Which Treatments Lead Neuropathic Pain Care?
METHODOLOGY:
Researchers conducted systematic searches in Embase, PubMed, the International Clinical Trials Registry, and ClinicalTrials.gov.
A total of 313 trials (284 pharmacologic and 29 neuromodulation studies) were analysed, comprising 48,789 adults treated for neuropathic pain.
The primary efficacy outcome was the proportion of participants achieving at least 50% or 30% reduction in baseline pain intensity or moderate pain relief, and the primary safety outcome was the number of participants who withdrew from treatment due to adverse events.
Nine neuromodulation and 89 pharmacologic interventions were assessed. For each treatment, risk differences were used to determine the number needed to treat (NNT) and the number needed to harm (NNH).
TAKEAWAY:
Strong recommendations were made for the use of TCAs (NNT, 4.6; NNH, 17.1; moderate certainty of evidence), alpha-2-delta ligands (NNT, 8.9; NNH, 26.2; moderate certainty of evidence), and SNRIs (NNT, 7.4; NNH, 13.9; moderate certainty of evidence) as first-line treatments.
Weak recommendations were made for the use of capsaicin 8% patches (NNT, 13.2; NNH, 1129.3; moderate certainty of evidence), capsaicin cream (NNT, 6.1; NNH, 18.6; very low certainty of evidence), and lidocaine 5% plasters (NNT, 14.5; NNH, 178.0; very low certainty of evidence) as second-line treatments.
Furthermore, weak recommendations were made for the use of botulinum toxin type A (NNT, 2.7; NNH, 216.3; moderate certainty of evidence), rTMS (NNT, 4.2; NNH, 651.6; low certainty of evidence), and opioids (NNT, 5.9; NNH, 15.4; low certainty of evidence) as third-line treatments.
IN PRACTICE:
"The recommendations highlight the need for shared decision making, prioritising patient autonomy and preferences when tailoring treatment strategies. Health-care professionals should adapt these guidelines to their specific contexts, accounting for the cost, accessibility, and feasibility of treatments," the authors wrote, emphasizing the need for further "placebo-controlled or sham-controlled trials done over clinically relevant timeframes."
SOURCE:
This study was led by Nadia Soliman, PhD, Imperial College London, London, England, and Xavier Moisset, MD, Université Clermont Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France. It was published online in the May 2025 issue of The Lancet Neurology .
LIMITATIONS:
This study was limited by potentially selective decision-making and heterogeneity in trial design, outcome measures, and reporting, thereby reducing precision. Crossover designs and inconsistent placebo responses may have contributed to changes in treatment effect estimates. Several studies lacked dose-response data, detailed adverse event reporting, and long-term follow-up, constraining safety assessments.
DISCLOSURES:
This study was funded by the NeuPSIG committee and ERA-NET Neuron. Several authors reported having various ties with various sources. Details are provided in the original article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
5 days ago
- Medscape
Methotrexate Success Varies in Ectopic Pregnancy Types
TOPLINE: Overall success rates for intramuscular (IM) methotrexate were comparable between recurrent and primary ectopic pregnancy cases, but single-dose treatment was less effective in recurrent cases. Analysis of 3944 patients revealed that multidose regimens achieved similar success rates in both groups, suggesting a potential benefit of routine multidose treatment for recurrent cases. METHODOLOGY: Researchers conducted systematic searches of MEDLINE, EMBASE, and Scopus databases through February 2025, following PRISMA guidelines for meta-analysis. Analysis included 3944 patients (502 with recurrent and 3442 with primary ectopic pregnancy) from 15 observational studies, with patients aged ≥ 18 years receiving IM methotrexate treatment. The primary outcome measure was treatment success, defined as complete resolution of ectopic pregnancy without requiring further intervention. TAKEAWAY: Single-dose IM methotrexate had lower success rates in patients with recurrent ectopic pregnancy than in those with a primary ectopic pregnancy (relative risk [RR], 0.79; 95% CI, 0.63-1.00; P = .050). Multidose IM methotrexate treatment showed no significant difference in success rates between recurrent and primary ectopic pregnancy groups (RR, 1.14; 95% CI, 0.71-1.84; P = .590). Substantial heterogeneity was observed among studies analyzing single-dose (I² = 73.0%) and multidose (I² = 64.0%) treatment outcomes. IN PRACTICE: 'Current observational data suggest that patients with recurrent ectopic pregnancy should be considered for multidose IM methotrexate to achieve similar rates of success compared with primary ectopic pregnancy,' wrote the authors of the study. SOURCE: The study was led by Shreya Bhat, MBChB, PGDipOMG, Department of Obstetrics and Gynaecology, Palmerston North Hospital, Te Whatu Ora MidCentral in Palmerston North, Aotearoa New Zealand. It was published online in Obstetrics & Gynecology. LIMITATIONS: According to the authors, substantial heterogeneity in outcome definitions and baseline cohort characteristics between studies affected the analysis. Most studies were retrospective cohort designs, introducing potential selection bias and confounding factors. The researchers noted that over 50% of studies failed to identify relevant confounding variables, which likely contributed to the large observed CIs for effect estimates. DISCLOSURES: The authors did not report any potential conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
5 days ago
- Medscape
NIPPV Outperforms NCPAP in Premature Infant Lung Care
TOPLINE: Nasal intermittent positive pressure ventilation (NIPPV) reduced the risk of requiring invasive ventilation and developing bronchopulmonary dysplasia by nearly half compared with nasal continuous positive airway pressure (NCPAP) in premature infants with respiratory distress syndrome. METHODOLOGY: Researchers conducted an updated meta-analysis of 14 randomized trials involving 1755 premature infants (< 37 weeks' gestation) with respiratory distress syndrome to compare NIPPV with NCPAP as their initial respiratory support. Data were gathered through systematic searches of Medline, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials for studies published between 1980 and February 2022. Primary outcomes were the incidence of invasive ventilation and bronchopulmonary dysplasia. Subgroup analyses were stratified by — infants who received surfactant treatment, gestational age (> 30 or ≤ 30 weeks), and birth weight (> or ≤ 1500 g). Secondary outcomes included mortality, pulmonary air leaks, retinopathy of prematurity stage ≥ 2, necrotizing enterocolitis Bell stage ≥ 2, and intraventricular hemorrhage grade ≥ 3. TAKEAWAY: NIPPV demonstrated superior efficacy with a 47% reduction in the incidence of invasive ventilation requirement (relative risk [RR], 0.53; P < .001) and a 49% reduction in the incidence of bronchopulmonary dysplasia (RR, 0.48; P = .004) compared with NCPAP. Benefits of NIPPV on invasive ventilation incidence persisted across subgroups defined by gestational age, birth weight, and surfactant treatment. However, reductions in bronchopulmonary dysplasia were significant only when stratified by gestational age. Secondary outcomes showed no significant differences between groups. No increase in pneumothorax was observed with NIPPV. IN PRACTICE: 'While these findings are promising, higher-quality randomized controlled trials with standardized protocols are needed before definitive clinical recommendations can be established,' the authors of the study wrote. SOURCE: This study was led by Juan Zeng, Southwest Hospital of Army Medical University, and Rong Tan, Jiulongpo People's Hospital, both in Chongqing, China. It was published online on June 28, 2025, in the European Journal of Pediatrics. LIMITATIONS: Although synchronized NIPPV may offer advantages over nonsynchronized NIPPV, insufficient data prevented subgroup comparisons of the two modes. As most trials enrolled infants with gestational age > 30 weeks, the findings may not be generalizable to extremely premature neonates. Finally, the overall low methodological quality and limited number of robust, high-quality studies reduce confidence in these conclusions. DISCLOSURES: The authors declared that they did not receive any funds, grants, or other support. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
18-07-2025
- Yahoo
Universities awarded funding to help recruit ‘world's top researchers' to UK
A group of leading universities and research organisations has been selected to deliver a £54 million Government fund to recruit world-leading researchers to the UK. The Global Talent Fund, administered by UK Research and Innovation (UKRI), aims to attract up to 80 researchers in high-priority sectors such as life sciences and digital technologies. Twelve universities and research institutions across the UK have secured an equal share of the fund to help bring some of the world's foremost researchers and their teams to the UK. The institutions selected are: University of Bath; Queen's University Belfast; University of Birmingham; University of Cambridge; Cardiff University; Imperial College London; University of Oxford; University of Southampton; University of Strathclyde; University of Warwick; John Innes Centre and MRC Laboratory of Molecular Biology. The five-year Government fund, which starts in 2025/26, will cover all eligible costs with no requirement for match funding from research organisations. Visa and relocation costs for researchers and their family members will be covered by the fund. Science minister Lord Vallance said: 'Genius is not bound by geography. But the UK is one of the few places blessed with the infrastructure, skills base, world-class institutions and international ties needed to incubate brilliant ideas, and turn them into new medicines that save lives, new products that make our lives easier, and even entirely new jobs and industries. 'Bringing these innovations to life, here in Britain, will be critical to delivering this Government's Plan For Change. 'My message to the bold and the brave who are advancing new ideas, wherever they are, is: our doors are open to you. 'We want to work with you, support you, and give you a home where you can make your ideas a reality we all benefit from.' Chancellor Rachel Reeves said: 'The UK is home to some of the world's best universities which are vital for attracting international top talent. 'Supported by our new Global Talent Taskforce, the Global Talent Fund will cement our position as a leading choice for the world's top researchers to make their home here, supercharging growth and delivering on our Plan For Change.'
